Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 35, 26 April 2024
Open
Access | Article
An overview of the principles and prospects of ADC drugs
* Author to whom correspondence should be addressed.
Abstract
ADC drugs, or antibody-drug conjugates, represent a class of specialized biopharmaceuticals employed in the treatment of neoplastic diseases and other specific medical conditions. ADCs are tailored therapeutics consisting of monoclonal antibodies covalently bonded to cytotoxic small-molecule payloads. These compounds gain entry into cancer cells by initiating endocytosis, ultimately deploying their intracellular cytotoxic agents to eliminate the malignancies. The theoretical advantage of such drugs is their ability to selectively target tumor tissue while sparing healthy cells. Since the introduction of the first ADC drug to the market in 2000, a surge of enthusiasm from diverse enterprises and research institutions has fueled the development and clinical evaluation of ADC drugs. Simultaneously, the field of ADC drug development has witnessed rapid advancements. This article aims to provide an overview of the fundamental structure and developmental evolution of ADC drugs, conduct a statistical analysis of ADC drugs currently in development, and explore potential future directions for the advancement of ADC drugs.
Keywords
Antibody-drug conjugates, Cancer, Clinical trials
References
1. Christakis P. (2011). The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand Round. The Yale journal of biology and medicine, 84(2), 169-172.
2. Köhler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495-497.
3. Ferrara, N., Hillan, K. J., & Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and biophysical research communications, 333(2), 328-335.
4. Plosker, G. L., & Figgitt, D. P. (2003). Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs, 63(8), 803-843.
5. Shefet-Carasso, L., & Benhar, I. (2015). Antibody-targeted drugs and drug resistance--challenges and solutions. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 18, 36-46.
6. Sievers, E. L., & Senter, P. D. (2013). Antibody-drug conjugates in cancer therapy. Annual review of medicine, 64, 15-29.
7. Norsworthy, K. J., Ko, C. W., Lee, J. E., Liu,J., John, C. S., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018). FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia. The oncologist, 23(9), 1103- 1108.
8. Fu,Z., Li, S., Han, S., Shi,C., & Zhang,Y. (2022). Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal transduction and targeted therapy, 7(1), 93.
9. De Cecco, M., Galbraith, D. N., & McDermott, L. L. (2021). What makes a good antibody-drug conjugate? Expert opinion on biological therapy, 21(7), 841-847.
10. Xu S. (2015). Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates. Pharmaceutical research, 32(11), 3577-3583.
11. https://en.wikipedia.org/wiki/Antibody-drug_conjugate#cite_note-:0-2
12. Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., Walter, R. B., Tallman, M. S., Stenke, L., & Appelbaum, F. R. (2013). A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood, 121(24), 4854-4860.
13. Wadleigh, M., Richardson, P. G., Zahrieh, D., Lee, S. J., Cutler, C., Ho, V., Alyea, E. P., Antin, J.H., Stone, R. M., Soiffer, R. J., & DeAngelo, D. J. (2003). Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102(5), 1578- 1582.
14. Xiao, Y., & Yu, D. (2021). Tumor microenvironment as a therapeutic target in cancer. Pharmacology & therapeutics, 221, 107753.
15. Kaytor, M. D., Wilkinson, K. D., & Warren, S. T. (2004). Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity. Journal of neurochemistry, 89(4), 962- 973.
16. Natsume, A., Niwa, R., & Satoh, M. (2009). Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC. Drug design, development and therapy, 3, 7- 16.
17. Tsumura, R., Manabe, S., Takashima, H., Koga, Y., Yasunaga, M., & Matsumura, Y. (2018). Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. Journal of controlled release : official journal of the Controlled Release Society, 284, 49-56.
18. Saunders K. O. (2019). Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Frontiers in immunology, 10, 1296.
19. Bargh, J. D., , Isidro-Llobet, A., , Parker, J. S., , & Spring, D. R., (2019). Cleavable linkers in antibody-drug conjugates. Chemical Society reviews, 48(16), 4361-4374.
20. NoltingB. (2013). Linker technologies for antibody-drug conjugates. Methods in molecular biology (Clifton, N.J.), 1045, 71- 100.
21. Jeffrey, S. C., Nguyen, M. T., Moser, R. F., Meyer, D. L., Miyamoto, J. B., & Senter, P. D. (2007). Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker. Bioorganic & medicinal chemistry letters, 17(8), 2278-2280.
22. Flygare, J. A., Pillow, T. H., & Aristoff, P. (2013). Antibody-drug conjugates for the treatment of cancer. Chemical biology & drug design, 81(1), 113-121.
23. Diamantis, N., & Banerji, U. (2016). Antibody-drug conjugates--an emerging class of cancer treatment. British journal of cancer, 114(4), 362-367.
24. Yang, H., Ganguly,A., & Cabral, F. (2010). Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. The Journal of biological chemistry, 285(42), 32242-32250.
25. Zein, N., Sinha, A. M., McGahren, W. J., & Ellestad, G. A. (1988). Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science (New York, N.Y.), 240(4856), 1198- 1201.
26. Gregson, S. J., Masterson, L. A., Wei, B., Pillow, T. H., Spencer, S. D., Kang, G. D., Yu, S. F., Raab, H., Lau, J., Li, G., Lewis Phillips, G. D., Gunzner-Toste, J., Safina, B. S., Ohri, R., Darwish, M., Kozak, K. R., Dela Cruz-Chuh, J., Polson, A., Flygare, J. A., & Howard, P. W. (2017). Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers. Journal of medicinal chemistry, 60(23), 9490-9507.
27. https://en.wikipedia.org/wiki/Gemtuzumab_ozogamicin
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-395-1
- ISBN (Online)
- 978-1-83558-396-8
- Published Date
- 26 April 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/35/20240721
- Copyright
- 26 April 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited